MedTrace Logo

A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL

NCT03018093 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-01-20

No results posted yet for this study

Summary

The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of C-CAR011 in treatment of adult subjects with relapsed/refractory CD19+ B cells acute lymphoblastic leukemia(r/r CD19+B-ALL)

Conditions

  • Relapsed or Refractory Acute Lymphoblastic Leukemia

Interventions

BIOLOGICAL

C-CAR-011

CD19-targeted chimeric antigen receptor T cells

Sponsors & Collaborators

  • Chinese PLA General Hospital

    collaborator OTHER

  • Shanghai AbelZeta Ltd.

    lead INDUSTRY

Principal Investigators

  • Li Yu · Chinese PLA General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
14 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-08-31
Completion
2018-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03018093 on ClinicalTrials.gov